EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

STAT3 Signaling in Oral Squamous Cell Carcinoma: Mechanisms, Tumor Microenvironment, Therapy Resistance, and Therapeutic Targeting

Giovanni Tossetta, Alessandro Polizzi, Gaetano Isola, Magdalena Smolik, Roberto Campagna

Medical Sciences · 17.11.2026 · 14 (7) · 793

DOI: 10.3390/medsci14070793 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Medical Sciences, online erschienen am 17.11.2026. Verfasst von Giovanni Tossetta und 4 weiteren Autor:innen. Die Arbeit nennt 123 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Oral squamous cell carcinoma (OSCC) remains a major clinical challenge because of late diagnosis, frequent recurrence, metastatic spread, and resistance to chemotherapy and radiotherapy. Signal transducer and activator of transcription 3 (STAT3) is a central signaling hub that integrates cytokine-, growth factor-, metabolic-, and stress-derived inputs in both malignant cells and the tumor microenvironment. This review summarizes canonical and non-canonical STAT3 activation and examines its contribution to OSCC initiation and progression. Persistent STAT3 signaling promotes proliferation, survival, epithelial–mesenchymal plasticity, invasion, angiogenesis, cancer stemness, metabolic adaptation, immune evasion, and resistance to treatment. Its activity is sustained by IL-6/JAK signaling, receptor and non-receptor tyrosine kinases, loss of negative regulators, non-coding RNAs, and reciprocal interactions with fibroblasts, macrophages, neutrophils, mesenchymal stromal cells, and suppressive myeloid populations. Therapeutic approaches include IL-6/JAK blockade, direct or proximal STAT3 inhibitors, decoy oligonucleotides, natural and repurposed compounds, and combinations with chemotherapy, radiotherapy, or immune-checkpoint inhibition. Although preclinical evidence is substantial, clinical translation remains limited by pathway heterogeneity, incomplete drug selectivity, systemic toxicity, and the absence of validated predictive biomarkers. Biomarker-guided trials and pharmacodynamically verified combination strategies are therefore required to establish STAT3 as a clinically actionable target in OSCC.

Zitieren

APA

Tossetta, G., Polizzi, A., Isola, G., Smolik, M., & Campagna, R. (2026). STAT3 Signaling in Oral Squamous Cell Carcinoma: Mechanisms, Tumor Microenvironment, Therapy Resistance, and Therapeutic Targeting. Medical Sciences, 14(7), 793. https://doi.org/10.3390/medsci14070793

Vancouver

Tossetta G, Polizzi A, Isola G, Smolik M, Campagna R. STAT3 Signaling in Oral Squamous Cell Carcinoma: Mechanisms, Tumor Microenvironment, Therapy Resistance, and Therapeutic Targeting. Medical Sciences. 2026;14(7):793. doi:10.3390/medsci14070793

BibTeX
@article{Tossetta2026,
  author = {Tossetta, Giovanni and Polizzi, Alessandro and Isola, Gaetano and Smolik, Magdalena and Campagna, Roberto},
  title = {STAT3 Signaling in Oral Squamous Cell Carcinoma: Mechanisms, Tumor Microenvironment, Therapy Resistance, and Therapeutic Targeting},
  journal = {Medical Sciences},
  year = {2026},
  volume = {14},
  number = {7},
  pages = {793},
  doi = {10.3390/medsci14070793}
}
Kostenlos starten →